drugset

drugset / Trial / NCT00018382

Insulin, Neurogenetics and Memory in Alzheimer's Disease

NCT00018382 ↗

Phase 2 Completed US Department of Veterans Affairs

RandomizedDouble-blindTreatment

Summary

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Timeline

Start: 1999-10
Primary completion: —
Completion: 2003-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosiglitazone	Small molecule	—	—

Indications